Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Review Article

Psychiatric Aspects of Chloroquine and Hydroxychloroquine Treatment in the Wake of Coronavirus Disease-2019: Psychopharmacological Interactions and Neuropsychiatric Sequelae

Brandon S. Hamm, M.D., M.S., Lisa J. Rosenthal, M.D., F.A.C.L.P., D.F.A.P.A.

Background: Chloroquine and hydroxychloroquine are among several experimental treatments being investigated in the urgent response to the coronavirus disease-2019. With increased use of these medications, physicians need to become knowledgeable of these drugs’ neuropsychiatric side effects and interactions with psychiatric medications. Objective: Clarify evidence base regarding the psychiatric side effects and psychiatric drug interactions of chloroquine and hydroxychloroquine. Methods: A literature review was performed in PubMed from 1950 to 2020 regarding psychiatric topics and targeted pharmacological properties of chloroquine and hydroxychloroquine. Results: First, chloroquine and hydroxychloroquine may mildly inhibit CYP2D6 metabolism of psychiatric medications, and psychiatric medications that interfere with CYP2D6 or CYP3A4 activity could alter chloroquine and hydroxychloroquine levels. Second, they may prolong the QT interval, warranting caution with concomitant prescription of other QT prolonging agents. Finally, neuropsychiatric side effects are very uncommon but possible and include a potentially prolonged phenomenon of “psychosis after chloroquine.” Hydroxychloroquine has less information available about its neuropsychiatric side effects than chloroquine, with psychosis literature limited to several case reports. Weak evidence suggests a possible association of hydroxychloroquine exposure and increased suicidal ideation. It is not clear whether patients with psychiatric illness are more vulnerable to neuropsychiatric sequel of these medications; however, overdose of these medications by suicidal patients has high risk of mortality. Conclusion: The risk of neuropsychiatric side effects of chloroquine and hydroxychloroquine when used for coronavirus disease-2019 treatment is not known. Best practice may include suicide risk assessment for patients treated with hydroxychloroquine. However, delirium is expected to be a more likely etiology of neuropsychiatric symptoms in critically ill patients treated for coronavirus disease-2019, and adjustment disorder is a much more likely etiology of anxiety and depression symptoms than the side effects of chloroquine or hydroxychloroquine.

(Psychosomatics 2020; 61:597–606)

Key words: chloroquine, hydroxychloroquine, psychiatry, neuropsychiatry, COVID-19.

INTRODUCTION

Chloroquine was developed subsequent to the bark extract quinine for the treatment and prophylaxis of malaria. Owing to potential toxicity and drug resistance, chloroquine and quinine are no longer in frequent use. Both chloroquine and hydroxychloroquine are
Chloroquine and Hydroxychloroquine Neuropsychiatry

Currently under investigation as possible treatments for patients infected with severe acute respiratory syndrome coronavirus 2 (which causes the disease coronavirus disease-2019 [COVID-19]). Several mechanisms have been suggested to explain how chloroquine and hydroxychloroquine may be therapeutic for COVID-19, including inhibition of viral binding to the host cell ACE2 receptor (is the mechanism for viral entry into host cells), inhibition of viral replication enzymes via raising host cell organelle pH, and de-escalation monocyte cytokine production (decreasing immune-mediated host tissue damage). These mechanisms could serve to inhibit virus entry into neurons and glia, slow replication of the virus in the brain and other tissues, and de-escalate the neuroinflammatory response (and delirium risk).

Chloroquine and hydroxychloroquine have been shown to inhibit severe acute respiratory syndrome coronavirus 2 in vitro. A Chinese commentary reported early favorable results in placebo-controlled trials of chloroquine treatment of COVID-19, and based on this early data, the Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province has published chloroquine dosing recommendations for COVID-19. Others have published recommendations to consider hydroxychloroquine instead of chloroquine for COVID-19 treatment, citing a superior side effect profile. Higher mortality was shown with COVID-19 treatment using higher dose chloroquine (600 mg twice daily) relative to a lower dose (450 mg twice daily) in a phase II double-blinded, randomized clinical trial. One large registry found increased mortality with chloroquine treatment, as well as increased risk of ventricular arrhythmia. Likely owing to the appeal of hydroxychloroquine’s superior side effect profile relative to chloroquine, more research is currently published on hydroxychloroquine treatment of COVID-19. One placebo-controlled randomized trial of 62 patients showed faster COVID-19 recovery time with hydroxychloroquine than placebo, and a large retrospective study suggested hydroxychloroquine benefits and minimal adverse effects. In contrast, many observational studies have not detected a mortality benefit with hydroxychloroquine treatment of COVID-19, and some studies even have suggested net adverse outcomes with hydroxychloroquine treatment for COVID-19 (cardiac, gastrointestinal).

In summary, chloroquine and hydroxychloroquine are not clearly evidenced to be beneficial in treatment of COVID-19 at this time, but are under further investigation and are being used (more hydroxychloroquine in the United States) in the setting of highly limited treatment options. Psychiatrists and other physicians may encounter patients on chloroquine and hydroxychloroquine for COVID-19 treatment, and this review aims to summarize the current psychiatric research on these medications to enable physicians to clarify what drug-drug interactions and possible neuropsychiatric side effects may need to be considered in clinical care.

Chloroquine and hydroxychloroquine have been in clinical use for more than 50 years, and both historic and current data relevant to psychiatry are presented. First, pertinent pharmacokinetic considerations and drug-drug interactions are discussed. Second, potential for QT prolongation is reviewed. We then provide an overview of central nervous system (CNS) side effects of chloroquine and hydroxychloroquine, followed by a comprehensive description of the current literature on neuropsychiatric side effects of chloroquine and hydroxychloroquine. Finally, more common alternate etiologies for psychiatric presentations in hospitalized patients with COVID-19 are briefly discussed.

**SEARCH STRATEGY**

References for this review were identified through searches performed in PubMed for articles published from January 1950 to March 2020, combining the terms “chloroquine” and “hydroxychloroquine” with terms “psychiatry,” “neurology,” “neuropsychiatry,” “depression,” “anxiety,” “psychosis,” “delirium,” “encephalopathy,” “memory,” “suicide,” “CYP450,” and “QTe.” Articles resulting from these searches and relevant references cited in those articles were reviewed. Articles were included with novel or recent content.

**PSYCHIATRICALLY RELEVANT PHARMACOLOGY**

**Pharmacokinetics and Drug Interactions**

Both chloroquine and hydroxychloroquine have a large volume of distribution with variable but prolonged elimination half-lives, ranging from 40 to 60 days. Chloroquine is known to be a mild 2D6 inhibitor and a substrate for CYP2C8 and CYP3A4, with minor CYP2D6 metabolism. Hydroxychloroquine is also a mild inhibitor of CYP2D6, and is metabolized by similar
CYP450s to chloroquine (CYP2D6, 2C8, 3A4, and 3A5). Potential CYP450 interactions among psychiatric medications and chloroquine or hydroxychloroquine are listed in Table 1 and Table 2. In addition, both chloroquine and hydroxychloroquine are partially renally excreted and require dose adjustment when a patient is in renal insufficiency to reduce risk of toxicity. Both chloroquine and hydroxychloroquine demonstrate dose-dependent inhibition of platelet aggregation. One study showed possible synergism for cardiovascular thromboprophylaxis with five or more years of concomitant administration of aspirin and hydroxychloroquine, but we were unable to find any studies evaluating the thrombotic impact of coadministering chloroquine or hydroxychloroquine concomitantly with psychiatric medications known to inhibit platelet aggregation, such as selective serotonin reuptake inhibitors.

### QT Interval Prolongation

Both chloroquine and hydroxychloroquine have been suspected to prolong the QT interval; however, the clinical significance of this is unclear. Although some studies demonstrate QT prolongation, others do not.

### CNS Side Effects

The most common CNS side effects of chloroquine are headache (6.4%), dizziness (5.3%), and insomnia (4.5%). Dose-dependent retinopathy can occur with chloroquine (less frequent with hydroxychloroquine),...
Chloroquine and Hydroxychloroquine Neuropsychiatry

and this requires monitoring with careful attention to the need for dose adjustment. In general, the side effects with hydroxychloroquine are similar to those with chloroquine, but are less common. Infrequent case reports have also reported dystonia and generalized tonic-clonic seizures after chloroquine administration.

Early symptoms of CNS toxicity include nausea and vomiting, dizziness, and headache, followed by delirium and seizures. Chloroquine has a narrow therapeutic window with rapid onset of toxicity symptoms and a 10–35% risk of mortality in overdose, another factor for psychiatrists to consider in patients with risk of overdose. CNS toxicity (and neuropsychiatric effects) may occur at therapeutic doses. Hydroxychloroquine overdose has less data but can also be fatal.

Several mechanisms of chloroquine have been proposed as contributors to chloroquine neuropsychiatric side effects: inhibition of neuronal calcium currents, dopamine excess, prostaglandin E antagonism, spermidine excess, and acetylcholine dysfunction. Furthermore, CNS levels of chloroquine are elevated 10–30 times over serum levels, possibly influenced by interference with P-glycoprotein function in the blood-brain barrier. Hydroxychloroquine is proposed to have many similar properties to chloroquine, and often hydroxychloroquine mechanisms of action are assumed based on chloroquine studies.

Neuropsychiatric events such as depression, mania, psychosis, and catatonia are present in less than 1–2% of patients on chloroquine. These events also seem to present less with hydroxychloroquine exposure than chloroquine exposure. Research regarding these phenomena is largely composed of case series and case reports and is described in the sections that follow.

**NEUROPSYCHIATRIC SIDE EFFECTS**

**Psychosis**

Although overall incidence is unknown, cases of “psychosis after chloroquine” have been described since 1958. A retrospective study by Biswas et al. describes 51 cases diagnosed as psychosis after chloroquine over the course of 10 years, extracted from the records of 22 psychiatric units in areas of India where malaria is hyperendemic. The inclusion criteria in this study were reasonable and included diagnostic criteria for substance-induced mood disorder, hallucinations or delusions in the absence of delirium, a minimum of 1 week of psychiatric symptoms, psychosis onset within 6 weeks of chloroquine initiation (at least one 150-mg tablet exposure), and resolution within 8 weeks of discontinuing chloroquine. Chloroquine levels were not drawn, so it is unclear what proportion of cases featured toxic levels. This study demonstrated that these psychosis presentations most commonly featured combined psychotic and affective symptoms (76.2% of cases). The most prevalent affective presentation was irritability with a mixed mood episode. Consistent with case series before this study, psychotic episodes were demonstrated to be prolonged (mean duration to resolution was 29.62 days after discontinuation of chloroquine). Psychosis after chloroquine is often described to feature derealization or depersonalization and the study by Biswas et al. found this was mostly present in the context of psychosis onset after significant stressors. The most common positive symptoms in the study were visual hallucinations, and most cases did not feature negative symptoms. In addition, psychosis after chloroquine is typically not related to premorbid psychiatric history, and patients are reported to have preserved insight during psychosis after chloroquine. A dose-response relationship between chloroquine dose and risk of psychotic symptoms has not been demonstrated. Chloroquine’s prolonged half-life and high CNS penetration are mechanisms proposed to explain the prolonged psychotic symptoms course after chloroquine discontinuation.

No studies were found regarding the incidence of hydroxychloroquine-induced psychotic symptoms. Six case reports describe psychosis suspected to be associated with hydroxychloroquine in diverse circumstances and were temporally related by hydroxychloroquine prescription preceding the onset of psychosis and resolving with hydroxychloroquine discontinuation. Hydroxychloroquine was prescribed for lupus presentations in three of these cases. In one report, the patient was suspected to have CNS toxicity owing to a pharmacy error resulting in 10-day exposure to an excessive hydroxychloroquine dose. Another case featured a patient with borderline personality disorder who developed auditory and kinesthetic hallucinations, as well as suicidal ideation during two hydroxychloroquine exposures that were five years apart. It is not clearly documented in all cases how lupus cerebritis was ruled out as a psychosis etiology, but one author...
used the Naranjo probability scale to evidence a hydroxychloroquine-induced psychosis etiology. The other three cases describe diverse psychotic presentations in the setting of hydroxychloroquine treatment for rheumatoid arthritis, Q fever, and erosive plantar lichen planus. The patient with rheumatoid arthritis developed disorganized psychosis with neurovegetative features. Another patient being treated for Q fever demonstrated an array of hallucinations (auditory and visual as well as formication) without disorientation or fluctuation of alertness. The final case was notable for concomitant methylprednisolone exposure, as well as an atypical psychotic presentation: early nightmares followed by depersonalization and cenesthetic hallucinations (false perception of viscera movement).

Mood Disorders

Mood episodes may occur without psychotic symptoms associated with chloroquine or hydroxychloroquine exposure. In a 1962 case series by Drew, 43% of 21 patients treated with chloroquine for rheumatoid arthritis developed mild-to-severe depression, with one patient’s depression being severe enough to warrant electroconvulsive therapy. The presence of rheumatic diseases could be a confounder for depression etiology in this small case series. Larger sample, malaria chemoprophylaxis studies do not demonstrate association of chloroquine exposure with such high incidence of depressive symptoms, although it is feasible that the higher doses of chloroquine used in treatment of rheumatological conditions could present an increased risk of incident depression than the lower doses used in malaria chemoprophylaxis. In a 1993 study evaluating a database of 40,726 patients on antimalarial chemoprophylaxis with chloroquine 300 mg weekly, depression was documented in 1.4% of the patients. Of note, the chloroquine dosing in this study is less than the dosing being used for COVID-19 treatment. In a 2009 four-arm, randomized, double-blinded, placebo-controlled study of mood profiles during malaria chemoprophylaxis, the study arm with 154 patients treated with chloroquine did not demonstrate increased depression symptoms, compared with controls. Of note, the chloroquine dose in this study (100 mg per day) is less than that being used for COVID-19. Furthermore, the study’s placebo group only took placebo for the first 1 week of a more than 6-week trial (transitioned to drug exposure after 1 wk), decreasing the validity of the placebo comparison. Finally, a 2013 nested case-control analysis of over 7 years of data from the United Kingdom General Practice Research Database demonstrated that the 34 cases of incident depression while on chloroquine chemoprophylaxis did not reflect a significant difference in depression risk compared with controls. A problematic feature of this study was that an incident case of depression would be linked to chloroquine if exposure was within 540 days before general practitioner diagnosis of depression, which seems like an inappropriately long duration at ascribe association.

Despite the apparent low frequency of chloroquine-associated depression in malaria chemoprophylaxis studies, several case reports describe patients who developed severe depressive episodes (often with suicidal ideation and psychotic features) within days of chloroquine exposure. A common feature of these cases was resolution of the depressive symptoms within several days of discontinuing chloroquine. Completed suicide via overdose on chloroquine has been previously reported, and fatal overdoses are possible at just a few times the therapeutic dose (often at 2–4 gram overdose). This should evoke caution in prescription of chloroquine for patients experiencing active suicidal ideations.

Several case reports describe manic episodes during chloroquine exposure, although no systematic studies are published. In these reports, onset of manic presentations was approximately 1 week after initiation of chloroquine exposure, with resolution 1–2 weeks after discontinuation of chloroquine. Classic manic symptoms were present in described cases, with notable grandiosity and frequent religiously-themed delusions. Patients were treated with haloperidol and chlorpromazine, as well as electroconvulsive therapy for one patient who developed catatonia.

Mood episodes associated with hydroxychloroquine have received less research attention. In a 2013 naturalistic study of patients receiving treatment for rheumatoid arthritis (n = 115), the 31 patients on hydroxychloroquine did not demonstrate an elevated risk for depression compared with other treatment groups. However, the patients on hydroxychloroquine scored significantly higher on severity of suicidal ideation in the Beck Scale for Suicidal Ideation (mean = 16.94 ± 11.09) than patients on methotrexate or leflunomide. Severity of suicidal ideation for patients taking hydroxychloroquine was still much lower than
with exposure to the biologic therapies (e.g., rituximab; mean = 25.73 ± 3.82). Given that this was a naturalistic study, clinical features that prompted the decisions for the one treatment over another could represent confounders in group comparison, and this was not clearly controlled for in the study. It is unclear whether these data can be meaningfully generalized to the context of persons taking hydroxychloroquine for COVID-19 prophylaxis or treatment. A 2018 review by Mascolo et al. evaluated the reports of hydroxychloroquine psychiatric side effects entered into the EudraVigilance pharmacovigilance database of the European Medicines Agency from 2001 to 2017. A total of 70 cases of depression and 53 cases of completed suicide were reported. Causation of these outcomes by hydroxychloroquine is certainly not clear from these pharmacovigilance data; however, the data do raise questions that warrant more formal study.

Anxiety

Anxiety has not received much attention as a psychiatric side effect of chloroquine, although several case reports have described panic episodes attributed to chloroquine exposure. In these cases, anxiety symptoms resolved within a few days of chloroquine discontinuation. In the 1966 case series by Drew, some patients described increased claustrophobia and nightmares during chloroquine exposure.

In the European Medicines Agency pharmacovigilance database from 2001 to 2017, 32 cases of anxiety disorders in the setting of hydroxychloroquine exposure and 59 cases of insomnia were reported. Furthermore, in the previously referenced 2013 study by Pinho de Oliveira Ribeiro et al., many of the patients on hydroxychloroquine treatment for rheumatoid arthritis were found to screen positive on the anxiety subscale of the Hospital Anxiety and Depression Scale (mean = 11, SD = 2.68). The anxiety scores in this group were significantly higher than scores of patients on methotrexate or leflunomide. Similar to the affective data from this rheumatoid arthritis treatment study, these data may not generalize well to the context of persons taking hydroxychloroquine for COVID-19 prophylaxis or treatment.

Neurocognitive Disorders

Some attention has been directed to consideration of hydroxychloroquine as an intervention for neurodegenerative disorders, based on its impact on lysosomal pH and immune system activation. A 2019 retrospective study in a large sample of patients with connective tissue disorders did not demonstrate a significant change in risk of developing Alzheimer’s dementia for patients exposed to chloroquine or hydroxychloroquine. Furthermore, in a 2018 double-blinded, randomized controlled trial of 168 subjects with early Alzheimer’s disease, the group with 18 months of treatment with hydroxychloroquine did not demonstrate significant difference compared with the placebo regarding dementia progression, cognitive performance, or behavior changes.

NEUROPSYCHIATRIC SYMPTOMS MORE EXPECTED IN PATIENTS HOSPITALIZED FOR COVID-19

Although no thorough studies on neuropsychiatric symptoms of COVID-19 have been published at the time this article was written, psychiatric presentations are expected to be common in hospitalized patients with COVID-19 because of etiologies other than chloroquine or hydroxychloroquine-induced neuropsychiatric side effects. Delirium has, anecdotally, been frequent in patients requiring intensive care. Critically ill patients frequently become delirious and may present with confusion, aggression, mood changes, hallucinations, delusional thinking, or other neuropsychiatric symptoms. In addition, survival of acute respiratory distress syndrome complicated by delirium has been associated with increased incidence of posttraumatic stress symptoms. In the study by Mao et al., nervous system–related clinical findings were present in 36.4% of 214 hospitalized COVID-19 cases, with the most common findings being stroke, ataxia, seizure, and “depressed level of consciousness.” Prevalence of neurological symptoms was increased to 45.5% in severe COVID-19 cases. In addition, a study of 58 patients with COVID-19 and acute respiratory distress syndrome showed that 69% of patients had agitation, and 65% were confused when neuromuscular blockade was discontinued. Within the discharged subgroup in this study, 33% demonstrated executive dysfunction. In addition to the physiological impact of COVID-19 and treatment exposures (i.e., sedatives, prolonged mechanical ventilation), several authors had noted that isolation introduces barriers to nonpharmacological measures to decrease the risk of delirium. Although a detailed consideration the
pathophysiology and treatment of delirium in COVID-19 is beyond the scope of this article, but comprehensive articles have been published elsewhere. 73–75 Additionally, case reports have been published regarding COVID-19 infection complicated by steroid-responsive encephalitis, 76 psychosis in patients without delirium, 77 and acute hemorrhagic necrotizing encephalopathy. 78

Increased depression, anxiety, memory deficits, insomnia, and posttraumatic stress disorder symptoms were demonstrated in survivors of severe acute respiratory syndrome coronavirus 1 and Middle East respiratory syndrome coronavirus infections, and these may be symptoms present in COVID-19 survivors as well. 79 Furthermore, in a survey one year after H1N1 influenza-associated acute respiratory distress syndrome, survivors reported high anxiety, depression, and posttraumatic stress disorder. 80 Patients hospitalized for pandemic-related infections, who do not experience delirium, may also experience adjustment disorder with depressive and/or anxious symptoms, as well as posttraumatic stress disorder. 81 Survivors of hospitalization for pandemic-related infections may also express pessimistic views, anger due to perception of rejection by society, and survivor grief. 82 Although no COVID-19 pandemic suicidology studies have been published at the time of this writing, some authors predict increased suicidality, based on previously demonstrated correlations with increased unemployment 83 and based on increased suicide rates during the 2003 severe acute respiratory syndrome coronavirus 1 epidemic. 84 Given the high expected incidence of psychiatric presentations during COVID-19 hospitalization, the infrequent neuropsychiatric side effects of chloroquine and hydroxychloroquine may be very difficult to clinically isolate in this population, though may be more clear to isolate in the setting of prophylactic use.

CONCLUSIONS

Anticipation of potential neuropsychiatric sequela from chloroquine and hydroxychloroquine treatment of COVID-19 requires extrapolation of chloroquine and hydroxychloroquine research in treatment of rheumatological disease and chemoprophylaxis for malaria. Neuropsychiatric side effects are uncommon in patients on chloroquine and hydroxychloroquine, although they are better described with chloroquine exposure than hydroxychloroquine exposure. Psychiatric symptom presentation during hospitalization for COVID-19 infection is much more likely to be due to delirium and adjustment disorder than neuropsychiatric side effects of chloroquine and hydroxychloroquine. The most studied neuropsychiatric phenomenon with these medications is “psychosis after chloroquine,” which may be prolonged in its resolution. Conversely, psychosis induced by hydroxychloroquine has been described only in a few case reports and should be expected to be quite rare. Weak evidence suggests potential for increased anxiety symptoms or suicidal ideation with hydroxychloroquine exposure, although this evidence is based on a very limited research with unclear generalization. Given that pandemic stressors and neuropsychiatric sequela of COVID-19 could possibly synergize with this possible increased suicide risk attributable to hydroxychloroquine, best practice may include screening for suicidal ideation and performance of a suicide risk assessment for patients on hydroxychloroquine for COVID-19 prophylaxis or treatment. Appropriate clinical practice can be better clarified by future research studying the association of hydroxychloroquine with suicidal ideation and suicide attempts, particularly in the setting of COVID-19 prophylaxis or treatment. Further psychiatric considerations include chloroquine and hydroxychloroquine’s mild CYP2D6 inhibition, the potential for psychiatric medications to impact chloroquine and hydroxychloroquine levels and toxicity, and the potential increased risk of TdP when chloroquine or hydroxychloroquine is combined with psychiatric medications that prolong the QT interval. The neuropsychiatric effects of chloroquine and hydroxychloroquine when used for treatment of COVID-19 have not been previously studied. Future research regarding the incidence and phenomenon of neuropsychiatric side effects in this clinical context may be helpful to guide future risk stratification.

Conflicts of Interest: Brandon Hamm has no conflicts of interest. Lisa Rosenthal has received a grant from Gilead Sciences for a study unrelated to this manuscript.

Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Acknowledgments: We would like to thank Arwen Mitchell for her feedback regarding the manuscript’s grammar and flow.
Chloroquine and Hydroxychloroquine Neuropsychiatry

References

1. Shanks GD: Historical review: problematic malaria prophylaxis with quinine. Am J Trop Med Hyg 2016; 95:269–272
2. Wani WA, Jameel E, Baig U, Mumtazuddin S, Hun LT: Ferroquine and its derivatives: new generation of antimalarial agents. Eur J Med Chem 2015; 101:534–551
3. Zhou D, Dai S-M, Tong Q: COVID-19 – a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother 2020; 75:1667–1670
4. Hu TY, Frieman M, Wolfram J: Insights from nanomedicine into chloroquine efficacy against COVID-19. Nat Nanotechnol 2020; 15:247–249
5. Wang M, Cao R, Zhang L, et al: Remdesivir and hydroxychloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30:269–271
6. Yao X, Ye F, Zhang M, et al: In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020;ciaa237
7. Gao J, Tian Z, Yang X: Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020; 14:72–73
8. Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia: Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi 2020; 43:185–188
9. Gauthret P, Lagier JC, Parola P, et al: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020;105949
10. Borba MGS, Val FFA, Sampaio VS, et al: Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection A randomized clinical trial. JAMA Netw Open 2020; 3:e208857
11. Mehra MR, Desai SS, Ruschitzka F, Patel AM: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet 2020. https://doi.org/10.1016/S0140-6736(20)31180-6
12. Chen Z, Hu J, Zhang Z, et al: Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. MedRxiv 2020. https://doi.org/10.1101/2020.03.22.20040758
13. Million M, Lagier JC, Gauthret P, et al: Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France. Travel Med Infect Dis 2020; 35:101738
14. Rosenberg ES, Dufort EM, Udo T, et al: Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state. JAMA 2020; 323:2493–2502
15. Magagnoli J, Narendran S, Pereira F, et al: Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19. MedRxiv 2020. https://doi.org/10.1101/2020.06.01
16. Mahévas M, Tran VT, Roumier M, et al: No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial. MedRxiv 2020. https://doi.org/10.1101/2020.04.10.20060699
17. Geleris J, Sun Y, Platt J, et al: Observational study of hydroxychloroquine in hospitalized patients with COVID-19. N Engl J Med 2020; 382:2411–2418
18. Tang W, Cao Z, Han M, et al: Hydroxychloroquine in patients mainly with mild to moderate COVID-19: an open-label, randomized, controlled trial. MedRxiv 2020. https://doi.org/10.1101/2020.04.10.20060558
19. Rainsford KD, Parke AL, Clifford-Rashotte M, Kean WF: Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology 2015; 23:231–269
20. Masimirembwa CM, Hasler JA, Johansson I: Inhibitory effects of antiparasitic drugs on cytochrome P450 2D6. Eur J Clin Pharmacol 1995; 48:35–38
21. Projean D, Baune B, Farinotti R, et al: In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isozymes catalyzing N-desethylchloroquine formation. Drug Metab Dispos 2003; 31:748–754
22. Somer M, Kallio J, Pesonen U, Pyykko K, Huupponen R, Scheinin M: Influence of hydroxychloroquine on the bioavailability of oral metoprolol. Br J Clin Pharmacol 2000; 49:549–554
23. Blockhart DA: [Internet]: Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine. Available from:https://drug-interactions.medicine.iu.edu; 2020
24. Tett S, Cutler D, Day R: Antimalarials in rheumatic diseases. Baillieres Clin Rheumatol 1990; 4:467–489
25. Pasanovic S, Pirovano L, Pischetts V, Faimundo M, Valenti G: Longterm hydroxychloroquine therapy and low-dose aspirin may have an additive effectiveness in the primary prevention of cardiovascular events in patients with systemic lupus erythematosus. J Rheumatol 2017; 44:1032–1038
26. Nosálová R, Jancinová V, Danielevová E: Chloroquine: a multipotent inhibitor of human platelets in vitro. Thromb Res 2000; 98:411–421
27. Tseng YL, Chiang ML, Lane HY, Su KP, Lai YC: Selective serotonin reuptake inhibitors reduce P2Y12 receptor-mediated amplification of platelet aggregation. Thromb Res 2013; 131:325–332
28. White NJ: Cardiotoxicity of antimalarial drugs. Lancet Infect Dis 2007; 7:549–558
29. Haesler IL, Chan XHS, Guérin PJ, White NJ: The arrhythmogenic cardiotoxicity of the quinoline and structurally related antimalarial drugs: a systematic review. BMC Med 2018; 16:200

30. Stas P, Faes D, Noyens P: Conduction disorder and QT prolongation secondary to long-term treatment with chloroquine. Int J Cardiol 2008; 127:e80–e82

31. Chen CY, Wang FL, Lin CC: Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia. Clin Toxicol 2006; 44:173–175

32. O’Laughlin JP, Mehta PH, Wong BC: Life threatening severe QTc prolongation in patient with systemic lupus erythematosus due to hydroxychloroquine. Case Rep Cardiol 2016; 2016:4626279

33. US Food & Drug Administration: FDA Cautions Against Use of Hydroxychloroquine or Chloroquine for COVID-19 Outside of the Hospital Setting or a Clinical Trial Due to Risk of Heart Rhythm. Available from: https://www.fda.gov/media/137250/download; 2020

34. Funk MC, Beach SR, Bostwick JR, et al: QTc prolongation and psychotropic medications. Am J Psychiatry 2020; 177:273–274

35. Steffen R, Fuchs E, Schildknecht J, et al: Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa. Lancet 1993; 341:1299–1303

36. Phillips-Howard PA, Kaile FO: CNS adverse events associated with antimalarial agents—fact or fiction? Drug Saf 1995; 12:370–383

37. Bhatia MS, Singhal PK, Dhar NK: Psychiatric complications of chloroquine. Ann Nat Acad Med Sci 1988; 24:223–228

38. Bhatia MS, Malik SC: Psychiatric complications of chloroquine. Indian Pediatr 1995; 32:351–353

39. Ball DE, Tagwireyi D, Nhachi CFB: Chloroquine poisoning in Zimbabwe: a toxicoepidemiological study. J Appl Toxicol 2002; 22:311–315

40. Clemessy JL, Taboulet P, Hoffman JR, et al: Treatment of acute chloroquine poisoning: a 5-year experience. Crit Care Med 1996; 24:1189–1195

41. Biswas PS, Sen D, Majumdar R: Psychosis following chloroquine ingestion: a 10-year comparative study from a malaria-hyperendemic district of India. Gen Hosp Psychiatry 2014; 36:181–186

42. Merino Argumánez CM, Sáez de La Fuente IS, Molina Collado ZM, Suárez Pita DS, Mestre Gómez B, Sanchez Izquierdo JA: Hydroxychloroquine, a potentially lethal drug. Med Intensiva 2017; 41:257–259

43. O’Shaughnessy TJ, Zim B, Ma W, et al: Acute neuropharmacologic action of chloroquine on cortical neurons in vitro. Brain Res 2003; 959:280–286

44. Lovestone S: Chloroquine induced mania. Br J Psychiatry 1991; 159:164–165

45. Malik-Ahmadi P: Toxic psychosis following use of quinacrine. J Clin Psychiatry 1981; 42:481

46. Richardson-Andrews RC: The side-effects of antimalarial drugs indicate a polyamine involvement in both schizophrenia and depression. Med Hypothesis 1985; 18:11–14

47. David KL, Berger PA: Pharmacological investigations of the cholinergic imbalance hypothesis of movement disorder and psychosis. Biol Psychiatry 1978; 13:23–26

48. Telgt DS, van der Ven AJ, Schimmer B, Sauerwein RWL: Serious psychiatric symptoms after chloroquine treatment following experimental malaria infection. Ann Pharmacother 2005; 39:551–554

49. Crowe A, Ilett KF, Karunajeewa HA, Batty KT, Davis TM: Antimalarial drugs indicate a polyamine involvement in both schizophrenia and depression. Med Hypothesis 1985; 18:11–14

50. Das P, Rai A, Chopra A, Philbrick K: Psychosis likely induced by hydroxychloroquine in a patient with chronic Q fever: a case report and clinically relevant review of pharmacology. Psychosomatics 2014; 55:409–413

51. Barrett PJ, Emmins PD, Clarke PD, Bradley DJ: Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travelers. BMJ 1996; 313:525–528

52. Schneider C, Adamcova M, Jick SS, et al: Antimalarial chemoprophylaxis and the risk of neuropsychiatric disorders. Travel Med Infect Dis 2013; 11:71–80

53. Burrell ZL, Martinez AC: Chloroquine and hydroxychloroquine in the treatment of cardiac arrhythmias. N Engl J Med 1958; 258:798–800

54. Ward W, Ryan W, Shehi G: Toxic psychosis: a complication of antimalarial therapy. J Am Acad Dermatol 1985; 12:863–865

55. Gonzalez SA, Costa-Juan E: Psychiatric symptoms induced by hydroxychloroquine. Lupus 2015; 24:339–340

56. Hsu W, Chiu N, Huang S: Hydroxychloroquine-induced acute psychosis in a systemic lupus erythematosus female. Acta Neuropsychiatr 2011; 23:318–319

57. Altintas E: Hydroxychloroquine-induced acute psychotic disorder in a female patient with rheumatoid arthritis: a case report. Dusunen Adam 2015; 28:369–373

58. Ferraro V, Mantoux F, Denis K, Lay-Macagno MA, Ortonne JP, Lacour JP: Hallucinations during treatment with hydroxychloroquine. Ann Dermatol Venereol 2004; 131:471–473

59. Drew JF: Concerning the side effects of antimalarial drugs used in the extended treatment of rheumatic diseases. Med J Aust 1962; 49:618–620

60. Schlagenhauf P, Johnson R, Schwartz E, Nothdurft HD, Steffen R: Evaluation of mood profiles during malaria chemoprophylaxis: a randomized, double-blind, four-arm study. J Travel Med 2009; 16:42–45

61. Das EM, Mohan M: Chloroquine-related depression. Indian J Psychiatry 1981; 23:184–185

62. Good MI, Shader RI: Lethality and behavioral side effects of chloroquine. J Clin Psychopharmacol 1982; 2:40–47

63. Akhtar S, Mukherjee S: Chloroquine induced mania. Int J Psychiatry Med 1993; 23:349–356

64. Bhatia MS, Jhanjee A, Oberoi A: A case of chloroquine-induced recurrent mania. Prim Care Companion CNS Disord 2012; 14. PCC.11101302

65. Pinho de Oliveira Ribeiro N, Rafael de Mello Schier A, Ornelas AC, Pinho de Oliveira CM, Nardi AE, Silva AC: Anxiety, depression and suicidal ideation in patients with...
rheumatoid arthritis in use of methotrexate, hydroxychloroquine, leflunomide and biological drugs. J Compr Psychiatry 2013; 54:1185–1189
66. Mascolo A, Berrino PM, Gareri P, et al: Neuropsychiatric clinical manifestations in elderly treated with hydroxychloroquine: a review article. Inflammopharmacology 2018; 26:1141–1149
67. Fardet L, Nazareth I, Petersen I: Chronic hydroxychloroquine/chloroquine exposure for connective tissue diseases and risk of Alzheimer’s disease: a population-based cohort study. Ann Rheum Dis 2019; 78:279–282
68. Van Gool WA, Weinstein HC, Scheltens PK, Walstra GJM: Effect of hydroxychloroquine on progression of dementia in early Alzheimer’s disease: an 18-month randomized, double-blind, placebo-controlled study. Lancet 2001; 358:455–460
69. Maldonado JR: Acute brain failure: pathophysiology, diagnosis, management, and sequelae of delirium. Crit Care Clin 2017; 33:461–519
70. Bashar FR, Vahedian-Azimi A, Hajiesmaili M, et al: Post-ICU psychological morbidity in very long ICU stay patients with ARDS and delirium. J Crit Care 2018; 43:88–94
71. Mao L, Jin H, Wang M, et al: Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol 2020; 77:1–9
72. Helms J, Kremer S, Merdji H, et al: Neurologic features in severe SARS-CoV-2 infection. N Engl J Med 2020; 382:2268–2270
73. Kotlis K, Roberson SW, Wilson JE, Dabrowski W, Pun BT, Ely EW: COVID-19 - ICU delirium management during SARS-CoV-2 pandemic. Crit Care 2020; 24:176
74. Sher Y, Rabkin B, Maldonado JR, Mohabir P: A case report of COVID-19 associated hyperactive delirium with proposed pathophysiology and treatment. Psychosomatics 2020. https://doi.org/10.1016/j.psym.2020.05.007
75. Beach SR, Praschan NC, Hogan C, et al: Delirium in COVID-19: a case series and exploration of potential mechanisms for central nervous system involvement. Gen Hosp Psychiatry 2020; 65:47–53
76. Pilotto A, Odolini S, Masiocchi S, et al: Steroid-responsive encephalitis in COVID-19 disease. Annu Neurol 2020. https://doi.org/10.1002/ana.25783
77. Ferrando SJ, Klepacz L, Lynch S, et al: COVID-19 psychosis: a potential new neuropsychiatric condition triggered by novel coronavirus infection and the inflammatory response? Psychosomatics 2020. https://doi.org/10.1016/j.psym.2020.05.012
78. Poyiadji N, Shahin G, Roujaim D, Stone M, Patel S, Griffith B: COVID-19-associated acute hemorrhagic necrotizing encephalopathy: CT and MRI features. Radiology 2020:201187
79. Rogers JP, Chesney E, Oliver D, et al: Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry 2020; 7:611–627
80. Luyt CE, Combes A, Becquemin MH, et al: Long-term outcomes of pandemic 2009 influenza A(H1N1)-associated severe ARDS. Chest 2012; 142:538–592
81. Hawryluck L, Gold WL, Robinson S, Pogorski S, Galea S, Stryra R: SARS control and psychological effects of quarantine, Toronto, Canada. Emerg Infect Dis 2004; 10:1206–1212
82. De Roo A, Ado B, Rose B, Guimard Y, Fonck K, Colebunders R: Survey among survivors of the 1995 Ebola epidemic in Kikwit, Democratic Republic of Congo: their feelings and experiences. Trop Med Int Health 1998; 3:883–885
83. Kawohl W, Nordt C: COVID-19, unemployment, and suicide. Lancet Psychiatry 2020; 7:389–390
84. Chan S, Chi F, Lam C, Leung P, Conwell Y: Elderly suicide and the 2003 SARS epidemic in Hong Kong. Int J Geriatr Psychiatry 2006; 21:113–118